Dynamic contrast-enhanced susceptibility-weighted perfusion imaging of intracranial tumors: A study using a 3T MR scanner

Diagnostic and Interventional Radiology

Volumn 15, Issue 1, 2009, Pages 3-12

  Şentürk, Senem ^a   Oǧuz, Kader Karli ^b   Cila, Ayşenur ^b  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

3 Tesla; Brain neoplasms; Magnetic resonance imaging; Perfusion weighted imaging

Indexed keywords

GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; BRAIN METASTASIS; BRAIN TUMOR; CANCER GRADING; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ECHO PLANAR IMAGING; FEMALE; GLIOBLASTOMA; GLIOMA; HEMANGIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG METASTASIS; MALE; MEDULLOBLASTOMA; MENINGIOMA; NEUROEPITHELIOMA; NUCLEAR MAGNETIC RESONANCE SCANNER; OLIGODENDROGLIOMA; PERFUSION WEIGHTED IMAGING; PRESCHOOL CHILD; RANK SUM TEST; SCHOOL CHILD; THREE DIMENSIONAL IMAGING;

ADOLESCENT; ADULT; AGED; BRAIN; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 66149156948     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Petrella JR, Provenzale JM. MR perfusion imaging of the brain: techniques and applications. AJR Am J Roentgenol 2000; 175:207-219.
2. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002; 223:11-29.
3. Keston P, Murray AD, Jackson A. Cerebral perfusion imaging using contrast-enhanced MRI. Clin Radiol 2003; 58:505-513.
4. Law M, Oh S, Babb JS, et al. Low grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology 2006; 238:658-667.
5. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 2006; 239:632-649.
6. Brant-Zawadski M. Pitfalls of contrast enhanced imaging in the nervous system. Magn Reson Med 1991; 22:243-248.
7. Daumas-Duport K, Sheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas: a simple and reproducible method. Cancer 1988; 62:2152-2165.
8. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-1763.
9. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359:845-848.
10. Aronen HJ, Gazit EI, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994; 191:41-51.
11. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast enhanced T2* weighted MR imaging. Neuroradiol 1999; 211:791-798.
12. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998; 171:1479-1486.
13. Wong JC, Provenzale JM, Petrella JR. Perfusion MR imaging of brain neoplasms. AJR Am J Roentgenol 2000; 174:1147-1157.
14. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from non-neoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000; 21:901-909.
15. Cha S, Pierce S, Knopp EA, et al. Dynamic contrast-enhance T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neiroradiol 2001; 22:1109-1116.
16. Ernst TM, Chang L, Witt MD, et al. Cerebral toxoplasmosis and lymphoma in AIDS: perfusion MR imaging experience in 13 patients. Radiology 1998; 208:663-669.
17. Erdogan C, Hakyemez B, Yildirim N, Parlak M. Brain abscess and cystic brain tumor: discrimination with dynamic susceptibility. contrast perfusion-weighted MRI. J Comput Assist Tomogr 2005; 29:663-667.
18. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastasis: differentiation by using perfusion and proton spectroscopic MR imaging. Neuroradiology 2002; 222:715-721.
19. Chiang CI, Kuo YT, Lu CY, et al. Distinction between high-grade gliomas and solitary metastasis using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiol 2004; 46:619-627.
20. Bulakbasi N, Kocaoglu M, Farzaliyev A, Tayfun C, Ucoz T. Somuncu I. Assessment of diagnostic accuracy of perfusion MR imaging in primary and metastatic solitary brain tumors. AJNR Am J Netroradiol 2005; 26:2187-2199.
21. Wetzel SG, Cha S, Law M, et al. Preoperative assessment of intracranial tumors with perfusion MR and a volumetric interpolated examination: a comparative study with DSA. AJNR Am J Neroradiol 2002; 23:1767-1774.
22. Shin JH, Lee HK, Kwun BD, et al. Using relative cerebral blood flow and volume to evaluate the histopatologic grade of cerebral gliomas: preliminary results. AJR Am J Roentgenol 2002; 179:783-789.
23. Rosen BR, Belliveau JE, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990; 14:249-265.
24. Villringer A, Rosen BR, Belliveau JW, et al. Dynamic imaging with lantanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med 1988; 78:41-55.
25. Rosen BR, Belliveau JW, Chien D. Perfusion imaging nuclear magnetic resonance. Magn Reson Q 1989; 5:263-281.
26. Axel L. Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. Radiology 1980; 137:679-686.
27. Ostergaard L, Sorenson AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. II. Experimental comparison and preliminary results. Magn Reson Med 1996; 36:726-736.
28. Weisskoff RW, Chesler D, Boxerman JL, Rosen BR. Pitfalls in MR measurement of tissue blood flow with intravascular tracers: which mean transit time? Magn Reson Med 1992; 29:553-559.
29. Leon PS, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996; 77:362-372.
30. Glantz MJ, Burger PC, Herdon JE II, et al. Influence of type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology 1991; 41:1741-1744.
31. Belliveau JW, Rosen BR, Kantor HL, et al. Functional cerebral imaging by susceptibility contrast NMR. Magn Reson Med 1990; 14:538-546.
32. Rosen BR, Belliveau JW, Aronen HJ et al. Susceptibility contrast MR imaging of cerebral blood volume: human experience. Magn Reson Med 1991; 22:293-299.
33. Boxerman JL. Hamberg LM. Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1996; 34:555-566.
34. Donahue KM, Krouwer HG, Rand SD, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000; 43:845-853.
35. Hakyemez B, Erdogan C, Ercan I, Ergin N, Uysal S, Atahan S. High-grade and low-grade gliomas: differentiation by perfusion MR imaging. Clin Radiol 2005; 60:493-502.
36. Andrew HAH, Laws ER Jr. Brain tumors, an encyclopedic approach. 2nd ed. New York, NY: Churchill Livingstone 2001; 29-45.
37. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24:1989-1998.
38. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligdendrogliomas. AJNR Am J Neuroradiol 2004; 25:214-221.
39. Cha S, Tihan T, Crawford F, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005; 26:266-273.
40. Law M, Kazmi K, Wetzal S, et al. Dynamic contrast-enhanced perfusion and conventional MR imaging findings for adult patients with cerebral primitive neuroectodermal tumor. AJNR Am J Neuroradiol 2004; 25:997-1005.
41. Spampinato MV, Smith JK, Kwock L, et al. Cerebral blood volume measurements and proton MR spectroscopy in grading oligodendroglial tumors. AJR Am J Roentgenol 2007; 188:204-212.
42. Strugar J, Rothbart D, Harrington W, Criscuolo GR. Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. J Neurosurg 1994; 81:560-566.
43. Bruening R, Wu RH, Yousry TA, et al. Regional relative blood volume MR maps of meningiomas before and after partial embolization. J Comput Assist Tomogr 1998; 22:104-110.
44. Principi M, Italiani M, Guiducci A, et al. Perfusion MRI in the evaluation of the relationship between tumour growth, necrosis and angiogenesis in glioblastomas and grade 1 meningiomas. Neuroradiol 2003; 45:205-211.